natgillin/translations-raw huggingface dataset:
What Sprimeo contains - The active substance is aliskiren (as hemifumarate) 300 mg. - The other ingredients are crospovidone, hypromellose, magnesium stearate, macrogol, 
Kaj vsebuje zdravilo Sprimeo - Zdravilna učinkovina je aliskiren (v obliki hemifumarata) 300 mg. - Pomožne snovi so: krospovidon, hipromeloza, magnezijev stearat, makrogol, mikrokristalna celuloza, povidon, brezvodni koloidni silicijev dioksid, smukec, titanov dioksid (E 171), črni železov oksid (E 172), rdeči železov oksid (E 172).
OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING PCTFE/PVC BLISTERS 
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA, KI VSEBUJE PCTFE/PVC PRETISNE OMOTE (VKLJUČENI PODATKI ZA “BLUE BOX”)
Pharmacovigilance system 
FARMACEVTSKI PODATKI
Not applicable 
Uporabno do
Rare: Musculoskeletal and connective tissue disorders Common: Renal and urinary disorders Uncommon: General disorders and administration site conditions Uncommon: Investigations Common: 
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti: Bolezni sečil občasni:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
Izgled zdravila Sprimeo in vsebina pakiranja
In hypertensive patients, once-daily administration of Sprimeo at doses of 150 mg and 300 mg provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to trough ratio for diastolic response of up to 98% for the 300 mg dose. 
Znižanje krvnega tlaka je bilo odvisno od velikosti odmerka in se je ohranilo skozi celoten 24-urni interval odmerjanja (ohranjena koristnost učinka v zgodnjih jutranjih urah).
As for other agents acting on the renin-angiotensin system, caution should be exercised when aliskiren is given in the presence of conditions pre-disposing to kidney dysfunction such as hypovolaemia (eg. 
Kot pri uporabi drugih zdravil, ki delujejo na sistem renin-angiotenzin, je potreba previdnost pri uporabi aliskirena pri bolnikih z drugimi boleznimi, zaradi katerih so bolj nagnjeni k slabšemu delovanju ledvic, kot so hipovolemija (na primer zaradi izgube krvi, hude ali dolgotrajne diareje, dolgotrajnega bruhanja in podobno), bolezni srca, jeter, sladkorna bolezen ali bolezen ledvic.
HOW TO STORE SPRIMEO 
SHRANJEVANJE ZDRAVILA SPRIMEO
Invented name 
(Izmišljeno) ime
Date of first authorisation: 15 March 2010 Date of latest renewal: 16 December 2014 
Datum prve odobritve: 15. marec 2010 Datum zadnjega podaljšanja: 16. december 2014
Your body can also make too much sugar. 
Tudi telo lahko proizvaja preveč sladkorja.
Do not take a double dose of this medicine. 
Ne vzemite dvojnega odmerka tega zdravila.
A double dose should not be taken on the same day. 
V istem dnevu ne sme vzeti dvojnega odmerka.
Based on a Cox model stratified by region. 
Na podlagi Coxovega modela, stratificiranega po regiji.
The relevance of these findings for humans is unknown. 
Pomen teh ugotovitev za človeka ni znan.
This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation. 
To lahko povzroči resne zdravstvene težave, kot so bolezni srca, bolezni ledvic, slepota ter amputacije.
You can take this medicine with or without food and drink. 
To zdravilo lahko jemljete s hrano in pijačo ali brez.
What is type 2 diabetes? 
Kaj je sladkorna bolezen tipa 2?
Secondary Outcome 
Sekundarni izid
Onset of these reactions occurred within the first 3 months after initiation of treatment, with some reports occurring after the first dose. 
Te reakcije so nastopile v prvih 3 mesecih po pričetku zdravljenja, v nekaterih primerih pa že po prvem odmerku.
Rare: reduced number of platelets 
Redki: zmanjšano število krvnih ploščic
However, when driving or using machines, it should be taken into account that dizziness and somnolence have been reported. 
Vendar pa je treba pri vožnji ali upravljanju strojev upoštevati, da so poročali o omotici in zaspanosti.
Diet and exercise can help your body use its blood sugar better. 
Dieta in telesna aktivnost pomagata pri boljši izrabi krvnega sladkorja.
Common: flu 
Pogosti: gripa
Because of the high safety margins, these findings do not suggest a relevant risk for human reproduction. 
Zaradi visoke meje varnosti te ugotovitve ne kažejo na relevantno tveganje za sposobnost razmnoževanja pri ljudeh.
Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
Pogostnost je definirana kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
STOP taking Ristaben and contact a doctor immediately if you notice any of the following serious side effects: 
Zdravilo Ristaben takoj PRENEHAJTE jemati in se posvetujte z zdravnikom, če opazite katerega koli od naslednjih resnih neželenih učinkov:
You should not stop taking this medicine without talking to your doctor first. 
Zdravila ne smete prenehati jemati, ne da bi se prej posvetovali z zdravnikom.
The renal clearance was approximately 350 ml/min. 
Ledvični očistek je bil približno 350 ml/min.
Uncommon: dry mouth 
Občasni: suha usta
Do not take Ristaben - if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Ristaben - če ste alergični na sitagliptin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
There was no difference in the incidence of severe hypoglycaemia. 
Razlike v pojavnosti hude hipoglikemije ni bilo.
What you need to know before you take Ristaben 
Kaj morate vedeti, preden boste vzeli zdravilo Ristaben
Common: swelling of the hands or legs 
Pogosti: otekanje dlani in nog
What Ristaben is and what it is used for 
Kaj je zdravilo Ristaben in za kaj ga uporabljamo
The mean dose of metformin was approximately 1,900 mg per day. 
Srednji odmerek metformina je bil približno 1.900 mg na dan.
For composite endpoints, the p-values correspond to a test of non-inferiority seeking to show that the hazard ratio is less than 1.3. 
Za sestavljene opazovane dogodke ustrezajo vrednosti p testiranju neinferiornosti z namenom dokaza, da je razmerje ogroženosti manjše od 1,3.
Your doctor may prescribe this medicine alone or with certain other medicines that lower blood sugar. 
Zdravnik vam lahko predpiše to zdravilo samo ali skupaj z določenimi drugimi zdravili za zniževanje krvnega sladkorja.
Therefore, meaningful interactions would not be expected with other p-glycoprotein inhibitors. 
Zato ni pričakovati pomembnih interakcij z drugimi zaviralci p-glikoproteina.
In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heart beat and other heart problems). 
Obvestite zdravnika zlasti, če jemljete digoksin (zdravilo za zdravljenje nepravilnega bitja srca in drugih težav s srcem).
No dose adjustment of digoxin is recommended. 
Prilagoditve odmerka digoksina ne priporočamo.
Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. 
Uporaba inhibitorjev DPP-4 je povezana s tveganjem za razvoj akutnega pankreatitisa.
Because increases of this magnitude are not clinically relevant, dosage adjustment in these patients is not necessary. 
Ker zvečanja takšnega obsega niso klinično pomembna, pri teh bolnikih prilagoditev odmerka ni potrebna.
Children and adolescents below 18 years should not use this medicine. 
Otroci in mladostniki do 18. leta starosti tega zdravila ne smejo jemati.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4 and 4.8). 
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1 (glejte poglavji 4.4 in 4.8).
When this happens, sugar (glucose) builds up in the blood. 
V takšnih primerih se sladkor (glukoza) kopiči v krvi.
The fraction of sitagliptin reversibly bound to plasma proteins is low (38 %). 
Delež sitagliptina, reverzibilno vezanega na plazemske beljakovine, je majhen (38 %).
There are no adequate data from the use of sitagliptin in pregnant women. 
Ni zadostnih podatkov o uporabi sitagliptina pri nosečnicah.
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required. 
V primeru prevelikega odmerjanja so smiselni običajni podporni ukrepi, npr. odstranitev neabsorbiranega zdravila iz prebavil, uvedba kliničnega nadzora (vključno s spremljanjem elektrokardiograma) in po potrebi uvedba podpornega zdravljenja.
Your doctor may ask you to stop Ristaben. 
Zdravnik vam bo morda naročil, da prenehate z jemanjem zdravila Ristaben.
If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg). 
Če imate težave z ledvicami, vam zdravnik lahko predpiše manjše odmerke zdravila (npr. 25 mg ali 50 mg).
The safety and efficacy of sitagliptin in children and adolescents under 18 years of age have not yet been established. 
Varnost in učinkovitost sitagliptina pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes. 
Zdravnik vam lahko predpiše zdravilo za zdravljenje alergijske reakcije ter drugo zdravilo za sladkorno bolezen.
Patients with an eGFR < 30 mL/min/1.73 m2 were not to be enrolled in the study. 
Bolniki z eGFR < 30 ml/min/1,73 m niso smeli biti vključeni v študijo.
Ristaben should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. 
Zdravila Ristaben se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 ali za zdravljenje diabetične ketoacidoze.
The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. 
Inkretini so del endokrinega sistema, ki sodeluje pri fiziološkem uravnavanju homeostaze glukoze.
You should not take this medicine during pregnancy. 
Med nosečnostjo tega zdravila ne smete jemati.
Approximately 79 % of sitagliptin is excreted unchanged in the urine. 
Približno 79 % sitagliptina se izloči z urinom v nespremenjeni obliki.
Do not throw away medicines via wastewater or household waste. 
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
There is no experience with doses above 800 mg in clinical studies. 
Izkušenj z odmerki, večjimi od 800 mg, iz kliničnih študij ni.
Opaque blisters (PVC/PE/PVDC and aluminum). 
Neprozorni pretisni omoti (PVC/PE/PVDC in aluminij).
If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid. 
Če opazite mehurje na koži, je to morda znak stanja, ki se imenuje bulozni pemfigoid.
• Severe and persistent pain in the abdomen (stomach area) which might reach through to your back with or without nausea and vomiting, as these could be signs of an inflamed pancreas 
• hudo in dolgotrajno bolečino v abdomnu (predelu trebuha), ki se lahko širi tudi v hrbet, s sočasno slabostjo in bruhanjem ali brez tega, saj ti znaki lahko kažejo na vnetje trebušne slinavke (pankreatitis).
If you take more Ristaben than you should If you take more than the prescribed dosage of this medicine, contact your doctor immediately. 
Če ste vzeli večji odmerek zdravila Ristaben, kot bi smeli Če ste vzeli večji odmerek tega zdravila od predpisanega, se takoj posvetujte z zdravnikom.
Tell your doctor if you have or have had: - a disease of the pancreas (such as pancreatitis) - gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood. 
Obvestite zdravnika, če imate ali ste kdaj imeli: - bolezen trebušne slinavke (kot je pankreatitis) - žolčne kamne ali zelo visoko vrednost trigliceridov (oblika maščob) v krvi ali če ste ali ste bili odvisni od alkohola.
Study 
Študija
See TECOS Cardiovascular Safety Study below. 
Glejte Študija srčno-žilne varnosti TECOS spodaj.
If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. 
Če se spomnite šele, ko je že čas, da vzamete naslednji odmerek, pozabljeni odmerek izpustite in nadaljujte z jemanjem zdravila ob predpisanem času.
Incidence rate per patientyears* N (%) 
Pojavnost na 100 bolnik-let* N (%)
Elderly subjects (65 to 80 years) had approximately 19 % higher plasma concentrations of sitagliptin compared to younger subjects. 
Pri starejših bolnikih (65 do 80 let) so bile plazemske koncentracije sitagliptina približno za 19 % večje kot pri mlajših osebah.
Due to lack of human data, Ristaben should not be used during pregnancy. 
Zaradi pomanjkanja podatkov pri ljudeh se zdravila Ristaben med nosečnostjo ne sme jemati.
Animal data do not suggest an effect of treatment with sitagliptin on male and female fertility. 
Podatki za živali ne kažejo na vpliv zdravljenja s sitagliptinom na plodnost samcev in samic.
Sitagliptin is not a substrate for OCT2 or OAT1 or PEPT1/2 transporters. 
Sitagliptin ni substrat za prenašalce OCT2 ali OAT1 ali PEPT1/2.
Further, GLP-1 does not impair the normal glucagon response to hypoglycaemia. 
Poleg tega GLP-1 ne zmanjša normalnega odziva glukagona na hipoglikemijo.
Your doctor may reduce the dose of your sulphonylurea or insulin medicine. 
Zdravnik vam bo morda zmanjšal odmerek sulfonilsečnine ali insulina.
Your doctor has prescribed this medicine to help lower your blood sugar, which is too high because of your type 2 diabetes. 
Zdravnik vam je to zdravilo predpisal, da vam bo pomagalo pri zniževanju krvnega sladkorja, ki je previsok zaradi sladkorne bolezni tipa 2.
The dose is 100 mg sitagliptin once daily. 
Odmerek je 100 mg sitagliptina enkrat na dan.
This medicine helps to increase the levels of insulin produced after a meal and decreases the amount of sugar made by the body. 
To zdravilo pomaga povečati količino insulina, ki nastane po obroku, in zmanjšuje nastajanje sladkorja v telesu.
Because of the high safety margin (19-fold at this no-effect level), these neoplastic changes are not considered relevant for the situation in humans. 
Zaradi visoke meje varnosti (19-kratna izpostavljenost brez škodljivega učinka) teh neoplastičnih sprememb nimamo za pomembne za klinično uporabo pri človeku.
For all other endpoints, the p-values correspond to a test of differences in hazard rates. 
Za vse druge opazovane dogodke ustrezajo vrednosti p testiranjem razlik razmerij ogroženosti.
(see section 4.2 and 5.2). 
(glejte poglavje 4).
Resolution of pancreatitis has been observed after discontinuation of sitagliptin (with or without supportive treatment), but very rare cases of necrotising or haemorrhagic pancreatitis and/or death have been reported. 
Opazili so, da je po prenehanju jemanja sitagliptina pankreatitis izginil (z ali brez podpornega zdravljenja), v zelo redkih primerih pa so poročali o nekrotizirajočem ali hemoragičnem pankreatitisu in/ali smrti.
Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. 
Bolnike je treba seznaniti z značilnim simptomom akutnega pankreatitisa, to je z dolgotrajno hudo bolečino v trebuhu.
Packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets and 50 x 1 film-coated tablets in perforated unit dose blisters. 
Pakiranja po 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženih tablet in 50 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek.
These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. 
Te reakcije vključujejo anafilaksijo, angioedem in eksfoliativna stanja na koži, vključno s Stevens-Johnsonovim sindromom.
TECOS Cardiovascular Safety Study 
Študija srčno-žilne varnosti TECOS
Adverse reactions are listed below (Table 1) by system organ class and frequency. 
Neželeni učinki so v nadaljevanju (preglednica 1) razvrščeni po organskih sistemih in pogostnosti.
If you forget to take Ristaben 
Če ste pozabili vzeti zdravilo Ristaben
What Ristaben is and what it is used for What you need to know before you take Ristaben How to take Ristaben 
Kaj je zdravilo Ristaben in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Ristaben Kako jemati zdravilo Ristaben Možni neželeni učinki
Other medicines and Ristaben 
Druga zdravila in zdravilo Ristaben
It is not known if this medicine is safe and effective when used in children and adolescents under 18 years of age. 
Ni znano, če je uporaba tega zdravila pri otrocih in mladostnikih do 18. leta starosti varna in učinkovita.
The difference was mainly due to a higher percentage of patients in the placebo group experiencing 3 or more episodes of hypoglycaemia (9.4 vs. 19.1 %). 
Razlika je bila v glavnem zaradi večjega odstotka bolnikov, ki so doživeli 3 ali več epizod hipoglikemije v skupini, ki je prejemala placebo (9,4 proti 19,1 %).
Improvement of surrogate markers of beta cell function, including HOMA-β (Homeostasis Model Assessment-β), proinsulin to insulin ratio, and measures of beta cell responsiveness from the frequently-sampled meal tolerance test were observed. 
Opazili so izboljšanje surogatnih markerjev funkcije beta celic, vključno s HOMA-β (Homeostasis Model Assessment-β), razmerjem proinsulin/insulin in meritvami funkcije beta celic pri tolerančnem testu s hrano (s pogostim vzorčenjem).
If you miss a dose, take it as soon as you remember. 
Pozabljeni odmerek vzemite takoj, ko se spomnite.
These changes in sitagliptin pharmacokinetics were not considered to be clinically meaningful. 
Te spremembe farmakokinetike sitagliptina niso smatrali za klinično pomembne.
If you have a serious allergic reaction (frequency not known), including rash, hives, blisters on the skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing, stop taking this medicine and call your doctor right away. 
V primeru hude alergijske reakcije (pogostnost neznana), ki vključuje izpuščaj, koprivnico, mehurje na koži/luščenje kože in otekanje obraza, ustnic, jezika ter žrela, kar lahko povzroči težave pri dihanju ali požiranju, prenehajte jemati to zdravilo in takoj pokličite zdravnika.
Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations. 
Sitagliptin je močan in močno selektiven zaviralec encima DPP-4 in v terapevtskih koncentracijah ne zavira zelo sorodnih encimov DPP-8 ali DPP-9.
Very common (may affect more than 1 in 10 people): low blood sugar Common: constipation 
Zelo pogosti (lahko se pojavijo pri več kot 1 od 10 ljudi): nizek krvni sladkor
Serious adverse reactions including pancreatitis and hypersensitivity reactions have been reported. 
Poročali so o resnih neželenih učinkih, vključno s pankreatitisom in preobčutljivostnimi reakcijami.
Dose-proportionality was not established for Cmax and C24hr (Cmax increased in a greater than dose-proportional manner and C24hr increased in a less than dose-proportional manner). 
Za vrednosti Cmax in C24ur niso ugotovili sorazmernega povečanja z odmerkom (vrednost Cmax se je povečevala bolj kot sorazmerno, vrednost C24ur pa se je povečevala manj kot sorazmerno).
This study involved 423 patients with chronic renal impairment (estimated glomerular filtration rate < 50 ml/min). 
Študija je vključevala 423 bolnikov s kronično ledvično okvaro (ocenjena hitrost glomerulne filtracije < 50 ml/min).
Cardiovascular death 
Srčno-žilna smrt
When considering the use of sitagliptin in combination with another anti-diabetic medicinal product, its conditions for use in patients with renal impairment should be checked. 
Pri presoji glede uporabe sitagliptina v kombinaciji z drugim antidiabetikom je treba preveriti pogoje za uporabo tega zdravila pri bolnikih z ledvično okvaro.
Sitagliptin is secreted in considerable amounts into the milk of lactating rats (milk/plasma ratio: 4:1). 
Pri doječih podganah se je sitagliptin v znatnih količinah izločal v mleko (razmerje mleko/plazma 4:1).
Do not use this medicine after the expiry date which is stated on the blister and the carton after 'EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli za oznako "EXP".
Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. 
Sitagliptin je substrat za humani organski anionski prenašalec-3 (hOAT-3 - human organic anion transporter-3), ki bi lahko bil vključen v izločanje sitagliptina skozi ledvice.
Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. 
Izločanje sitagliptina poteka primarno preko ledvične sekrecije in vključuje aktivno tubularno sekrecijo.
In vitro data showed that sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4 and CYP1A2. 
In vitro pridobljeni podatki kažejo, da sitagliptin ni zaviralec izoencimov CYP CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 ali 2B6 in ni induktor CYP3A4 ter CYP1A2.
Combination Therapy Studies 
Študije kombiniranega zdravljenja
In a two-day study in healthy subjects, sitagliptin alone increased active GLP-1 concentrations, whereas metformin alone increased active and total GLP-1 concentrations to similar extents. 
V dvodnevni študiji pri zdravih osebah je sitagliptin sam povečal koncentracijo aktivnega GLP-1, pri čemer je tudi sam metformin v podobnem obsegu povečal koncentracijo aktivnega in celokupnega GLP-1.
Hypoglycaemia has been reported in combination with sulphonylurea (4.7 %-13.8 %) and insulin (9.6 %) (see section 4.4). 
O hipoglikemiji so poročali pri kombinaciji s sulfonilsečnino (4,7 % - 13,8 %) in z insulinom (9,6 %) (glejte poglavje 4.4).
Two studies were conducted to evaluate the efficacy and safety of sitagliptin monotherapy. 
Izvedeni sta bili dve študiji, ki sta ovrednotili učinkovitost in varnost sitagliptina kot samostojnega zdravila.
These included hypoglycaemia (frequency very common with the combination of sulphonylurea and metformin), influenza (common with insulin (with or without metformin)), nausea and vomiting (common with metformin), flatulence (common with metformin or pioglitazone), constipation (common with the combination of sulphonylurea and metformin), peripheral oedema (common with pioglitazone or the combination of pioglitazone and metformin), somnolence and diarrhoea (uncommon with metformin), and dry mouth (uncommon with insulin (with or without metformin)). 
Ti so vključevali hipoglikemijo (pogostnost - zelo pogosta v kombinaciji s sulfonilsečnino in metforminom), gripo (pogostnost - pogosta z insulinom (z ali brez metformina)), navzeo in bruhanje (pogostnost - pogosta z metforminom), flatulenco (pogostnost - pogosta z metforminom ali pioglitazonom), zaprtje (pogostnost - pogosta v kombinaciji s sulfonilsečnino in metforminom), periferni edem (pogostnost - pogosta s pioglitazonom ali v kombinaciji s pioglitazonom in metforminom), zaspanost in diarejo (pogostnost - občasna z metforminom) in suha usta (pogostnostobčasna z insulinom (z ali brez metformina)).
The effect of potent CYP3A4 inhibitors in the setting of renal impairment has not been assessed in a clinical study. 
Učinkov močnih zaviralcev CYP3A4 pri ledvični okvari v klinični študiji niso ovrednotili.
The renal clearance of sitagliptin was not meaningfully altered. 
Ledvični očistek sitagliptina se ni pomembno spremenil.
In this study, the proinsulin to insulin ratio, a marker of efficiency of insulin synthesis and release, improved with sitagliptin and deteriorated with glipizide treatment. 
V tej študiji se je razmerje proinsulin/insulin, ki je označevalec učinkovitosti sinteze in sproščanja insulina, pri zdravljenju s sitagliptinom izboljšalo, pri zdravljenju z glipizidom pa poslabšalo.
Hazard Ratio (95% CI) 
Razmerje ogroženosti (95 % IZ)